AnxA1 administration regulated platelet function directly (eg, via reducing thromboxane B<sub>2</sub> and modulating phosphatidylserine expression) to promote cerebral protection post-I/RI and act as an effective preventative strategy for stroke by reducing platelet activation, aggregate formation, and cerebral thrombosis, a prerequisite for ischemic stroke.